Complete Guide to Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients Pharmacokinetics
Overview
Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients is a Menin inhibitor used in the Oncology / Acute myeloid leukemia therapeutic area. It is indicated for Relapsed/refractory NPM1-mutated acute myeloid leukemia. Free ziftomenib population PK simulator for relapsed/refractory NPM1-mutated AML. Explore 600 mg QD dosing, food, PPI, strong CYP3A4 inhibitor effects, and KO-739/KO-516 metabolite exposure from Mitra et al. 2026.
Mechanism of Action
Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients exerts its pharmacological effect by targeting Menin-KMT2A interaction. As a Menin inhibitor, it modulates this target to achieve therapeutic efficacy in Relapsed/refractory NPM1-mutated acute myeloid leukemia. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published Population PK with linked metabolites models for Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients:
| Parameter | Value |
|---|---|
| Q | 27.7 L/h |
| CL | 11.6 L/h |
| Ka | 0.0928 1/h |
| Vc | 54.6 L |
| Vp | 1106 L |
| dose | 600 mg once daily |
| route | Oral |
| KO516 CL | 21.7 L/h |
| KO739 CL | 8.50 L/h |
| lag time | 0.325 h |
| metabolites | KO-739 and KO-516 |
| ppi effect F1 | 0.627 multiplier |
| ppi effect Ka | 0.616 multiplier |
| food effect F1 | 6.09-fold increase |
| bioavailability | 0.129 fasted baseline |
| strong cyp3a4 inhibitor effect CL | 0.459 multiplier |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology / Acute myeloid leukemia therapeutic area, for the treatment of Relapsed/refractory NPM1-mutated acute myeloid leukemia, understanding the pharmacokinetics of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients PK Simulator
Explore Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients?
The elimination half-life of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients depends on patient-specific factors. Use our interactive Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients administered?
Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients is administered via the Oral route. It is indicated for Relapsed/refractory NPM1-mutated acute myeloid leukemia. As a Menin inhibitor, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients?
Key pharmacokinetic parameters for Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.